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Abstract
This report is the third part of a trilogy from a multidisciplinary study which was undertaken to investigate gene and protein expression in a large cohort of patients with well defined and diverse clinical phenotypes. The aim of part 3 was to review which of the analytical techniques that we had used would be the most useful for differential diagnosis, and which would provide the most accurate indication of disease severity. Careful clinical appraisal is very important and every DMD patient was correctly diagnosed on this basis. In contrast, half of the sporadic BMD patients and all of the sporadic female patients had received different tentative diagnoses based on clinical assessments alone. Sequential observations of quantitative parameters (such as the time taken to run a fixed distance) were found to be useful clinical indicators for prognosis. Intellectual problems might modify the impression of physical ability in patients presenting at a young age. Histopathological assessment was accurate for DMD but differentiation between BMD and other disorders was more difficult, as was the identification of manifesting carriers. Our data on a small number of women with symptoms of muscle disease indicate that abnormal patterns of dystrophin labelling on sections may be an effective way of differentiating between female patients with a form of limb girdle dystrophy and those carrying a defective Xp2l gene. Dystrophin gene analysis detects deletions/duplications in 50 to 90% of male patients and is the most effective non-invasive technique for diagnosis. Quantitative Western blotting, however, would differentiate between all Xp2l and non-Xp2l male patients. In this study we found a clear relationship between increased dystrophin abundance (determined by densitometric analysis of blots) and clinical condition, with a correlation between dystrophin abundance and the age at loss of independent mobility among boys with DMD Thus, in part 3 of this report we discuss which techniques were most useful for differentiating patients with DMD and BMD from those with other neuromuscular disorders, and for predicting what degree of disease severity might be expected. Since patients with DMD may require a wheelchair before they are 7 years old and patients with BMD may never need one, an accurate prognosis would help the families of affected patients to adjust their lives and homes to the future needs of a young patient.
Materials and methods
The patient groups are defined in part 1, together with details of their clinical assessment. Techniques for genetic and protein analyses are described in parts 1 and 2. A figure illustrating Western blot lanes is shown in part 1. The clinical data and results of gene and protein expression are summarised in the Appendix in part 1.
Results

CLINICAL ASSESSMENT
Observation of the patients provides the basis for differential clinical diagnosis and this opinion may then be substantiated or contradicted by subsequent laboratory investigations. In this study there were no examples of initial clinicopathological misdiagnosis among patients now known to have DMD. In contrast, 1 1/35 (31 fig 1A,B) .
Among male patients, the relationship between dystrophin labelling on sections and blots was simple in that both increased in parallel. In this study only two BMD patients had labelling which was indistinguishable from non-Xp2l on sections labelled with one or more antibodies, but the differentiation was not clear cut in a further five patients with an overall decrease in labelling intensity without really significant variation between and within fibres. In these cases where a subjective opinion was uncertain, densitometric analysis of blots was able to show a reduction in dystrophin abundance by more quantitative methods. Among the female patients the correlation between dystrophin labelling on tissue sections and on blots was not as strong as in the male groups. For example, two female patients (S98 and S99 in the appendix in part 1) both had the same proportions of fibres labelled (60% normal, 20% decreased, 20% negative) but the abundance of dystrophin was estimated to be 32 to 45% of normal for patient S98 and 70 to 80% of normal for patient S99. This was mainly because of the difficulty of discriminating between fibres with truly 'normal' immunolabelling and those with slightly decreased labelling.
In this study we found that the mean values for dystrophin abundance increased gradually across the clinical groups from severe DMD in group 1 to typical BMD in group 5 (see part 1 of this investigation). Almost 60% of DMD patients from groups 1 and 2 had low levels of dystrophin synthesised from mRNA in which the reading frame must have been restored. Since the presence of in frame dystrophin molecules is associated with milder clinical phenotypes, it was possible that this might have some prognostic significance. We therefore used results obtained with the rod domain antibody, Dy4/6D3, to examine more closely the correlation between clinical severity and estimates of dystrophin abundance. We used the age at which boys lose the ability to walk independently (requiring full length callipers or a wheelchair) as a measure of muscle strength. Excluding an atypical DMD patient (S39, who had a BMD-like dystrophin profile), and three patients with deletions which removed the Dy4/6D3 antibody binding site, a total of 33 DMD patients and seven intermediate D/BMD patients had lost independently mobility at the end of the study when results were collated. Quantitative estimates of dystrophin abundance were obtained from densitometric analysis of dystrophin bands on blots. Among the set of 40 patients a significant positive relationship (r = 0-66, p < 0-000001) was found between the age when boys could no longer walk independently and the abundance of dystrophin determined with the rod MAb Dy4/6D3 (fig 2) . It was also noted that, as dystrophin abundance on blots increased, so did the incidence of a particular pattern of labelling on tissue sections. This consisted of a high proportion of fibres with very weak label- Age at loss of independent mobility
Figure 2 Age at loss of independent mobility and dystrophin abundance estimated from blots labelled with the rod MAb Dy4/6D3. In general, estimates of dystrophin abundance increased with the length of time that boys maintained independent mobility. The correlation coefficient for the data on these 40 patients is 0-66 which is highly significant (p < 0-00001 Immunocytochemistry of dystrophin using multiple antibodies, combined with the use of 0-spectrin labelling as an essential indicator of membrane integrity, is extremely cost effective when compared with Western blotting (which is rather labour intensive and expensive). All cases of DMD and more than 80% of BMD cases could be detected from labelling of tissue sections. Most, if not all, manifesting carriers show dystrophin protein abnormalities32-36 and therefore immunocytochemical analysis is an effective way of differentiating between a sporadic female with a form of limb-girdle dystrophy and a manifesting carrier of a defective Xp2l gene. In addition, an unknown proportion of non-manifesting carriers of DMD24323437 or BMD3839 may show abnormal dystrophin labelling. Data from larger numbers of non-manifesting obligate carriers would be required to assess the reliability of dystrophin analysis in carrier detection.
Although immunocytochemistry is cost effective, there are very distinct advantages to the additional use of blots, in which all the immunoreactive protein present is detected. For example, if a sample has been thawed, or subjected to degradation (for example, some fetal material), labelling on sections may appear patchy or absent but the detection on blots of clearly labelled breakdown products with abnormally low molecular mass will prevent misdiagnosis. We are not aware of any examples in published reports where dystrophin analysis by Western blotting has failed to detect a patient with confirmed DMD or BMD, so it is tentatively assumed that all male patients could be detected by this form of protein analysis.
Blots may be used to estimate dystrophin abundance and this may be a very sensitive prognostic indicator. In this study we have shown that there is a gradual increase in dystrophin abundance (DMD < D/BMD < BMD) with improving clinical condition, and prognoses based on dystrophin abundance are currently being monitored very closely. In this study we have found a clear correlation between dystrophin abundance and the age at which DMD and intermediate D/BMD boys lost the ability to walk independently. As more of the boys become unable to walk we will be able to confirm or revise our original observation. It should be emphasised that these data are not being used in any formal counselling of families with DMD. The correlation, while statistically significant, was not absolute and a few patients with relatively high dystrophin levels lost mobility earlier than the population average of 9 years. Conversely, three boys with undetectable dystrophin on blots (but a few fibres labelled on sections) remained ambulatory until they were more than 10 years old. A possible explanation for this apparent discrepancy is that the biopsy sample taken for 
